Mutant p53 Combination Therapy With MDM2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer, particularly those with p53 mutations, are challenging to treat due to the inactivation of the p53 tumor suppressor protein, leading to uncontrolled cell proliferation and metastasis, with existing therapies failing to effectively restore wild-type p53 function.
Innovation Solution
Administering a compound that binds to mutant p53 to reconform it to a conformation with anti-tumor activity, combined with inhibitors of MDM2, PI3K, or AKT, to enhance the therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat p53-mutant cancer, then treatment is simpler, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines multiple therapeutic agents into a single treatment regimen: a p53 reactivating compound (such as APR-246 or eprenetapopt) is administered together with MDM2 inhibitors (such as idasanutlin or RG7112). This merging of therapies addresses the insufficient efficacy of single-agent treatments while managing complexity through coordinated administration protocols.
Solution Approach 2:
The treatment uses composite therapeutic approaches combining compounds with different mechanisms of action: p53 reactivating agents that restore wild-type conformation and MDM2 inhibitors that prevent p53 degradation. This composite strategy enhances overall therapeutic efficacy by targeting multiple aspects of p53 dysfunction simultaneously.
2Reliability
If p53 function is restored using single-agent therapy, then treatment is simpler, but anti-tumor activity is insufficient
Solution Approach 1:
The patent merges p53 reactivation therapy with MDM2 inhibition in a coordinated treatment regimen. The p53 reactivating compound restores functional conformation to mutant p53, while the MDM2 inhibitor prevents p53 degradation and enhances its stability. This combination produces synergistic anti-tumor effects that exceed the sum of individual agent activities.
Solution Approach 2:
The patent uses MDM2 inhibitors as intermediary agents that mediate between the p53 reactivating compound and the tumor cells. By blocking MDM2-mediated p53 degradation, these intermediaries enhance and prolong the anti-tumor activity of the p53 reactivating agents, creating a more effective therapeutic response.
3Duration of action of moving object
If combination therapy with MDM2 inhibitor is administered, then median survival time increases by at least 50%, but treatment complexity increases
Solution Approach 1:
The patent combines p53 reactivating compounds with MDM2 inhibitors in a unified treatment regimen that has been shown to increase median survival time by at least 50% in preclinical models. The combination leverages complementary mechanisms: p53 reactivation restores tumor suppressor function while MDM2 inhibition prevents p53 degradation, creating sustained anti-tumor activity that prolongs survival.
Solution Approach 2:
The patent employs preliminary reactivation of p53 function before administering MDM2 inhibitors, ensuring that functional p53 protein is present and stabilized. This preliminary action of restoring p53 conformation creates a foundation that enhances the subsequent effectiveness of MDM2 inhibition, maximizing survival benefit while managing treatment complexity through optimized sequencing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly increases median survival time in cancer patients by restoring p53 function, inducing apoptosis, inhibiting angiogenesis, and arresting cell cycle progression, demonstrating at least a 50% improvement in median survival time in controlled studies.
Implementation Method 1
a compound, wherein the compound binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity
Implementation Method 2
administering to the subject a therapeutically-effective amount of an MDM2 inhibitor
Implementation Method 3
inducing apoptosis, inhibiting angiogenesis, and arresting cell cycle progression
Implementation Method 4
inducing apoptosis, inhibiting angiogenesis, and arresting cell cycle progression
Data Source
AI summary
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a tumor with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with an MDM2, PI3K, or AKT inhibitor to reduce the progression of cancers that contain a p53 mutation.